There are estimates of the possible reduced timeline regarding market access for health technologies as a result of a more efficient Health Technology Assessment process.

This is of course dependent on the current procedures in a given Member State. A recent study(1) found that within a sample of 16 countries, the availability of joint clinical assessment at the time of marketing authorisation can speed up market access in 12 of them by a period ranging from 2 to 6 weeks.

The impacts of this 2-6 weeks of earlier access can have significant benefits for all relevant stakeholders. Notably, patients could receive treatment more quickly with an impact on improving their health condition.

(1) https://www.efpia.eu/media/219813/cra-efpia-european-cooperation-on-hta-impact-assessment-final-report-july-2017-stc.pdf